课题基金 / 基金详情

项目摘要

项目成果

ALBERT CRAIG LOCKHART的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/摘要 本申请旨在加强Paul Calabresi临床和转化肿瘤学培训计划, 南卡罗来纳州医科大学(MUSC)的Hollings癌症中心(HCC)-被称为 HCC Calabresi K12项目。Hollings癌症中心是美国唯一一家NCI指定的癌症中心。 南卡罗来纳州。发展创新和有影响力的临床和转化研究, 血液和实体肿瘤恶性肿瘤是HCC的最高战略目标。组织成几个强大的, 主题,跨学科的研究计划,HCC已经朝着这一目标取得了实质性进展。这 K12计划为下一代科学家提供了准备和加快翻译的机会 将科学带入临床。随着新的领导层,HCC正在进行战略扩张,重点是 关于招募和提升医学科学家的问题。虽然一个强大的癌症管道集中在 HCC-MUSC提供研究培训,从高中到本科,研究生和 博士后培训机会,HCC Calabresi K12计划是唯一由NCI资助的早期职业教师 南卡罗来纳州的发展项目。作为旗舰项目,它教育和培养初级调查员, 所谓的卡拉布雷西学者,在过渡到研究独立之前的关键时刻,在一个强大的 癌症研究人员之间的团队科学文化涵盖了广泛的学科。程序 建立在HCC和MUSC的突出优势之上,包括:1)强大的共享基础设施 研究资源; 2)多样化和不断增长的患者群体; 3)NIH资助的临床和转化 科学奖(CTSA)计划与临床研究科学硕士(MSCR)选项; 4)计划 教师导师,由基础和医生科学家组成,他们有良好的跟踪记录, 资助合作转化研究,5)转化癌症的主要机构投资 research.本申请中确定的40名课程教师导师和卡拉布雷西学者组成 HCC以病人为中心的研究的核心。
英文摘要
PROJECT SUMMARY / ABSTRACT This application proposes to enhance the Paul Calabresi Clinical & Translational Oncology Training Program at the Hollings Cancer Center (HCC) of the Medical University of South Carolina (MUSC) – referred to as the HCC Calabresi K12 Program. The Hollings Cancer Center is the only NCI-designated cancer center in the State of South Carolina. Development of innovative and impactful clinical and translational research in hematologic and solid tumor malignancies is the top strategic goal for the HCC. Organized into several strong, thematic, interdisciplinary research programs, the HCC has made substantial progress towards this goal. This K12 Program provides the next generation of scientists the opportunity to prepare and expedite the translation of science into the clinic. With new leadership, the HCC is undergoing strategic expansion, with an emphasis on the recruitment and advancement of physician-scientists. While a robust pipeline of cancer focused research training is offered at HCC-MUSC, which spans from high school to undergraduate, graduate and postdoc training opportunities, the HCC Calabresi K12 Program is the only NCI-funded early career faculty development program in South Carolina. As the flagship program, it educates and nurtures junior investigators, called Calabresi Scholars, at the critical juncture prior to transitioning to research independence in a strong culture of team science among cancer investigators encompassing a broad range of disciplines. The program builds on the outstanding strengths of the HCC and MUSC including: 1) a robust infrastructure of shared research resources; 2) a diverse and growing patient population; 3) a NIH funded Clinical and Translational Science Award (CTSA) program with a Master of Science in Clinical Research (MSCR) option; 4) Program Faculty Mentors, comprised of basic and physician scientists, who have well-established track records and funding in collaborative translational research, and 5) a major institutional investment in translational cancer research. The 40 Program Faculty Mentors identified in this application and the Calabresi Scholars constitute the core of patient-oriented research at the HCC.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
IV期或复发性非小细胞肺癌中的一线Nivolumab。
DOI: 10.1056/nejmoa1613493
发表时间: 2017-06-22
期刊: The New England journal of medicine
影响因子: --
作者: [Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA, CheckMate 026 Investigators]
通讯作者: CheckMate 026 Investigators
Harnessing the IL-7/IL-7Rα axis to improve tumor immunotherapy.
利用 IL-7/IL-7Rα 轴改善肿瘤免疫治疗。
DOI: 10.1080/2162402x.2015.1122865
发表时间: 2016
期刊: Oncoimmunology
影响因子: 7.2
作者: [Johnson,CBryce, Wrangle,John, Mehrotra,Shikhar, Li,Zihai, Paulos,ChrystalM, Cole,DavidJ, Surh,CharlesD, Rubinstein,MarkP]
通讯作者: Rubinstein,MarkP
Cancer-Directed Surgery for Mesothelioma: A Team Sport.
间皮瘤癌症定向手术:一项团队运动。
DOI: 10.1016/j.chest.2023.02.036
发表时间: 2023
期刊: Chest
影响因子: 9.6
作者: [Gibney,BarryC, Detterbeck,FrankC]
通讯作者: Detterbeck,FrankC
DOI: 10.1016/j.coph.2018.04.009
发表时间: 2018-08
期刊: Current opinion in pharmacology
影响因子: 4
作者: [Mills JN, Rutkovsky AC, Giordano A]
通讯作者: Giordano A
Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction
  • 批准号:
    7275889
  • 项目类别:
  • 资助金额:
    $28.53万
  • 财政年份:
    2007
  • 负责人:
    ALBERT CRAIG LOCKHART
  • 依托单位:
Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction
  • 批准号:
    7774121
  • 项目类别:
  • 资助金额:
    $26.43万
  • 财政年份:
    2007
  • 负责人:
    ALBERT CRAIG LOCKHART
  • 依托单位:
RESPONSE TO PACLITAXEL RELATED TO GENITIC VARIATINS IN MDR1
  • 批准号:
    7375601
  • 项目类别:
  • 资助金额:
    $0.13万
  • 财政年份:
    2005
  • 负责人:
    ALBERT CRAIG LOCKHART
  • 依托单位:
CORRELATION ON THE PHARMACOKINETICS AND TOXICITY OF CPT-11 WITH FUNCTIONALLY
  • 批准号:
    7375615
  • 项目类别:
  • 资助金额:
    $0.13万
  • 财政年份:
    2005
  • 负责人:
    ALBERT CRAIG LOCKHART
  • 依托单位:
海外基金